美银证券发表报告指，翰森制药(03692.HK) 旗下阿美替尼片(almonertinib)在今年首两个月销售额激增76.9%，带动公司销售表现强劲，因此上调2025、2026及2027年收入预测各1.9%、2.5%及2.7%，目标价由24.8元升至29元。由于其稳健的研发能力及现有主要产品的适应症扩充，重申“买入”评级。
(ha/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-28 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.